Legend

Supplementary Figure 1

Adoptive therapy of anti-VEGFR2 CAR transduced T cell treatment modulated intratumoral MDSCs in tumor bearing mice. C57BL/6 mice bearing 12 days-old B16 tumor were sublethaly irradiated with 5 Gy TBI and treated with genetically engineered syngeneic T cells essentially as described in Fig. 5. Tumors and spleens of 3 mice from each group were excised at different time points post therapy and processed to obtain single cell suspensions and analyzed by flow cytometry. Percentage of the $CD11b^{+}Gr1^{+}$ myeloid subsets was determined in total viable fraction of the cell preparations by FACS. Absolute cell numbers $CD11b^{+}Gr1^{+}$ cells were determined by multiplying the percentage of $CD11b^{+}Gr1^{+}$ cells by the total number of viable cells. (A) A representative FACS data from single cell preparations of spleen and tumor tissues from one mouse in each group obtained on day 6 day post-ACT showing the percentage $CD11b^{+}Gr1^{+}$ cells gated in the in total viable populations. (B) Pooled data obtained from three mice from each group collected at three different time points post T cell therapy showing the percentage and total number of $CD11b^{+}Gr1^{+}$ cells in spleen and tumor tissues. Data represented as mean $\pm$ SEM.